Introduction {#Sec1}
============

Since the completion of the Human Genome Project, much emphasis has been placed on cataloguing human DNA variation and understanding its impact on susceptibility to human diseases. The most common form of sequence polymorphism is the single base substitution. Single nucleotide polymorphisms (SNPs) occur on average once every 180 basepairs in the human genome (Crawford et al. [@CR13]). A catalogue of common DNA variation is now well-developed in at least one population (Carlson et al. [@CR4]; Reich et al. [@CR28]), and new resources provided by the International HapMap Project (The International HapMap Consortium [@CR34], [@CR35]) and Perlegen (Hinds et al. [@CR18]), among others, offer useful information and tools for genetic association studies for applying common SNPs in different population samples.

While public databases are useful for mining information about common SNPs, the databases are less useful and complete for rare variants. Rare sequence variants, defined here as having a minor allele frequency of \<1%, are not well-described most likely because of the number of chromosomes required to discover them (Kruglyak and Nickerson [@CR21]). It is possible that both common and rare variation will be required to aid investigators in developing approaches for successful genetic association study designs. For example, one common design for association studies, the common disease/common variant approach, assumes that common DNA variation rather than rare DNA variation is associated with susceptibility to common human diseases (Collins et al. [@CR11]). However, many advocate the possibility that many rare variants, each with a small contribution, underlie the susceptibility to common human diseases (Pritchard and Cox [@CR26]). The arguments are further complicated by study designs that genotype "tagSNPs" and rely on linkage disequilibrium to identify the causative SNP ("indirect") versus genotyping known nonsynonymous SNPs ("direct"; Botstein and Risch [@CR1]).

As views of common variation emerge, empirical data on how to obtain rare variation and its application in the context of a genetic association study are needed in this age where "medical" re-sequencing is becoming possible (Gibbs [@CR15]). To provide these data, we have chosen to examine these issues using the gene C-reactive protein (*CRP*). *CRP* is an ideal model for deep or medical re-sequencing because it is a small gene (\~2 kb) whose protein product is well studied as an established general marker for predicting cardiovascular disease and risk of myocardial infarction (Danesh et al. [@CR14]). Furthermore, sequence variation for *CRP* has been described in several smaller studies (Brull et al. [@CR2]; Cao and Hegele [@CR3]; Kovacs et al. [@CR20]; Russell et al. [@CR29]; Wolford et al. [@CR36]), only one of which has identified nonsynonymous variation within the gene (Miller et al. [@CR23]). Here, we describe the re-sequencing of a single gene, *CRP*, for the purpose of cataloguing both common and rare variation, and we also describe the possible application of the discovered variants in population-based survey using both "indirect" and "direct" association study designs. We demonstrate that while deep re-sequencing or re-sequencing in several racial/ethnic populations results in the identification of rare, potentially damaging nonsynonymous SNPs, the effort may not necessarily translate to a better understanding of the gene's impact on human phenotypes when applied to larger cohorts linked to quantitative phenotypes.

Materials and methods {#Sec2}
=====================

Sequencing {#Sec3}
----------

As part of NHLBI's Program for Genomic Applications, SeattleSNPs re-sequences genes involved in inflammation, lipid metabolism, and blood pressure regulation for genetic variation discovery in two population samples: European-Americans (*n*=23) and African-Americans (*n*=24) obtained from Coriell Cell Repository. The European-American samples are members of the CEPH panel (NA12560, NA12547, NA10845, NA10853, NA10860, NA10830, NA10842, NA10851, NA07349, NA10857, NA10858, NA10848, NA12548, NA10844, NA10854, NA10861, NA10831, NA10843, NA10850, NA07348, NA10852, NA06990, NA07019) and the African-American samples are members of the African-American panel of 50 (NA17101-NA17116; NA17133-NA17140). Additional sequencing for variation discovery was performed on samples from the Polymorphism Discovery Resource Panel (PDR450)(Collins et al. [@CR12]) and several other population samples obtained from Coriell Cell Repository, including seven Chinese (NA16654, NA16688-NA16689, NA17014-NA17017), seven Japanese (NA17051-NA17057), ten Southeast Asians (NA17081-NA17090), ten Mexicans (NA17061-NA17070), and six Indo-Pakistanis (NA17021-NA17024; NA17026-NA17027).

All samples were re-sequenced for variation discovery in *CRP* on an ABI3730 using standard Big Dye terminator chemistry. A detailed laboratory protocol can be found on the SeattleSNPs website (see [Websites](#Sec11){ref-type="sec"}). A total of 6.8 kb was re-sequenced for *CRP*, including all exons, all introns, 1.7 kb 5′ flanking, and 2.8 kb 3′ flanking. SNPs were numbered based on the GenBank accession number AF449713 and were submitted to dbSNP. The SNP number does not correspond with the translation start site. The location, rs number (where available), and sequence context of the SNPs described here can be found in Supplementary Table 1. All SNP allele frequencies and 95% confidence intervals for each population sample are given in Supplementary Table 2.

Haplotypes were inferred using PHASEv2.1.1 (Stephens et al. [@CR32]; Stephens and Donnelly [@CR31]) using SNPs with a minor allele frequency of \>5%. Inferred haplotypes and their counts are given in Supplementary Table 3 for each population sample. TagSNPs were determined using LDSelect with a minor allele frequency \>5% and *r*^2^\>0.64 (Carlson et al. [@CR5]). The predicted effects of all nonsynonymous variation were explored computationally using PolyPhen (Ramensky et al. [@CR27]) and SIFT (Ng and Henikoff [@CR24]).

Genotyping {#Sec4}
----------

Standard TaqMan^®^ Assays by Design^®^ were developed to genotype two sites newly discovered in *CRP*: 2513 and 2612. The sequence for the primers and Taqman^®^ probes for 2513 was 5′-GATCGTGGAGTTCTGGGTAGATG-3′ (forward), 5′-ACAGTGTATCCCTTCTTCAGACTCT-3′ (reverse), 5′-CACCCTGGGCTTC-3′ (C allele probe), and 5′-TCACCCTGAGCTTC-3′ (T allele probe). For 2612, the primers and probes were 5′-GGGCAGGAGCAGGATTCC-3′ (forward), 5′-AGTCCCACATGTTCACATTTCCAAT-3′ (reverse), 5′-ACTTTGAAGGAAGCCAG-3′ (G allele probe), and 5′-ACTTTGAAGAAAGCCAG-3′ (A allele probe). The two assays were validated, and individuals identified as heterozygous for 2612 were confirmed by re-sequencing.

DNA samples (*n*=7,296) from the National Health and Nutrition Examination Survey (NHANES) III were genotyped for the two sites by Taqman^®^. The genotyping success rate was 97% for both SNPs. NHANES III is a population-based sample of Americans collected regardless of health status between 1988 and 1994, and DNA was collected for phase 2 of the survey (1991--1994). All DNA samples are linked to an extensive collection of laboratory phenotypes, such as serum CRP levels, as well as survey data. Survey design and ascertainment of NHANES III as well as descriptions of the phenotypic variables can be found at CDC's National Center for Health Statistics website (see [Websites](#Sec11){ref-type="sec"}). The three largest racial/ethnic groups for NHANES III include non-Hispanic whites (*n*=2,630), non-Hispanic blacks (*n*=2,108), and Mexican-Americans (*n*=2,073). A small number of samples (*n*=137) were duplicates or not linked to the phenotypic data and were not included in subsequent analyses.

Results {#Sec5}
=======

SNP discovery {#Sec6}
-------------

Three sets of population samples were re-sequenced for variation discovery in *CRP* with different goals: (1) the standard SeattleSNPs population samples re-sequenced for mostly common variation discovery in European-Americans (*n*=23) and African-Americans (*n*=24); (2) an extended DNA panel of Asians (Chinese, *n*=7; Japanese, *n*=7, Southeast Asian, *n*=10), Mexicans (*n*=10), and Indo-Pakistanis (*n*=6) for population-specific variation discovery; and (3) the Polymorphism Discovery Resource Panel (PDR; *n*=450) for rare coding variation discovery (Collins et al. [@CR12]). Both the SeattleSNPs and extended DNA panels have sufficient power to identify common SNPs (minor allele frequency \>5%); however, the range of power depends on the number of chromosomes re-sequenced for each population sample. Thus, the African-American and combined Asian samples have the highest detection rate for common SNPs (99%), and the Indo-Pakistani sample has the lowest detect rate for common SNPs (\>80%)(Kruglyak and Nickerson [@CR21]). The PDR can detect 99% of SNPs with a MAF of at least 1% (Kruglyak and Nickerson [@CR21]).

To determine whether SeattleSNPs is capturing all *CRP* common variation found in many populations by re-sequencing only European- and African-American samples, we compared the SNPs identified by the usual SeattleSNPs DNA panel to the extended DNA panel containing samples of Asian, Mexican, and Indo-Pakistani ancestry. From these two DNA panels, a total of 40 SNPs were identified (Fig. [1](#Fig1){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}). As expected, a greater number of SNPs was identified in the African-American population sample (30) compared with the Asian (17), Mexican (13), European-American (13), and Indo-Pakistani (11) population samples (Table [1](#Tab1){ref-type="table"}). Also, an increase in nucleotide diversity as well as a greater number of haplotypes was observed in the African-American population samples compared with the other population samples (Table [1](#Tab1){ref-type="table"}). Approximately half (58%) of the 40 SNPs are private to one population sample, most of which were found in the African-American population sample (14 SNPs). The inclusion of the extended DNA panel allowed the identification of nine SNPs not identified in the SeattleSNPs panel. Two of the nine new sites were common (\>5% MAF) within the Indo-Pakistani population sample (sites 974 and 2513). Fig. 1*CRP* variants identified re-sequencing the SeattleSNPs (*n*=47) and extended DNA panels (*n*=40). SNPs are numbered across the top of the figure in order of discovery in the reference sequence. Individual samples are labeled to the left of the figure. Each *square* represents the genotype of a SNP for each individual: homozygous common (*blue*), heterozygous (*red*), and homozygous rare (*yellow*). *Gray* represents missing data. *Abbreviations*: African-American (*D*), European-American (*E*), extended panel DNA (*V31-36*: Indo-Pakistani, *V80-89*: Mexican; and *V71-77, V130-139, V321-327*: Asian)Table 1Sample size (chromosomes), number of segregating sites (*S*), nucleotide diversity (*θ*), and number of inferred haplotypes for *CRP* re-sequenced in several samplesSample*NS* (MAF\>5%)*θ* (10^−4^)Haplotypes (heterozygosity)African-Americans4830 (18)11.9618 (0.86)European-Americans4613 (10)5.257 (0.76)Asians4817 (9)6.8411 (0.67)Mexicans2013 (11)6.326 (0.74)Indo-Pakistanis1211 (11)7.176 (0.75)Total17440 (17)11.8329 (0.86)

Among the 40 SNPs identified in *CRP*, one unique variant is the high frequency triallelic SNP 1440 (rs3091244). All three alleles of 1440, A, C, and T, occur with appreciable frequency in the African-American (0.33, 0.26, and 0.41) and European-American (0.05, 0.62, and 0.33) population samples. Examination of the extended DNA panel reveals that the combined Asian population sample of Chinese, Japanese, and Southeast Asian samples is also polymorphic for all three 1440 alleles (0.19, 0.75, and 0.06); however, the allele frequency distribution in the combined Asian population sample is very different compared with the African- and European-American population samples. The Mexican population sample does not contain all three alleles, possibly due to the smaller sample size of this collection compared with the other three population samples. Among chromosomes of Mexican-descent, the C allele occurs more frequently (0.75) than the T allele. Finally, among the Indo-Pakistani samples, the C allele is predominant over the A allele (0.83 vs. 0.17). Again, the absence of the third allele (T) may be due to the small sample size of this population collection compared with the larger collections.

Coding variation {#Sec7}
----------------

One of the sites identified in the Indo-Pakistani sample, SNP 2513 (MAF=0.08), is a nonsynonymous SNP (Pro133Lys) in exon 2 of *CRP*. Site 2513 is predicted to be "possibly damaging" by PolyPhen but "tolerated" by SIFT (Table [2](#Tab2){ref-type="table"}a). Also, site 2475 identified in two heterozygous individuals from the Japanese population sample is a novel synonymous SNP in exon 2 (Table [2](#Tab2){ref-type="table"}a). Table 2*CRP* variants identified in the coding regionSiteNucleotide changeAmino acid change (position)Number of chromosomes (panel)SIFT/PolyPhen prediction(a) Nonsynonymous 2314T \> CTyr to His (67)1/794 (PDR)Tolerated/benign 2513C \> TPro to Lys (133)1/80 (extended)Tolerated/possibly damaging 2612G \> AGly to Glu (166)1/828 (PDR)Tolerated/possibly damaging(b) Synonymous 2220T \> GThr to Thr (35)7/700 (PDR)N/A 2244G \> APro to Pro (43)3/734 (PDR)N/A 2475C \> TSer to Ser (120)2/80 (extended)N/A 2667 (rs1800947)G \> CLeu to Leu (184)36/826 (PDR)N/A*PDR* Polymorphism Discovery Resource panel

Given the possibility that *CRP* contains previously unidentified rare and potentially population-specific nonsynonymous SNPs, we re-sequenced *CRP* in individuals from the Polymorphism Discovery Resource Panel (PDR450) primarily to discover novel coding variation. The PDR450 samples are not linked to racial/ethnic identifiers; therefore, the panel is useful for DNA variation discovery, but not for allele frequency estimation for specific populations. Overall, 46 sites were identified in the PDR, 61% of which were not found among the SeattleSNPs and extended DNA panel samples. All novel sites in the PDR had a minor allele frequency of 2% or less (Supplementary Table 2). Among these novel sites, we identified two additional nonsynonymous SNPs, sites 2314 (Tyr67His) and 2612 (Gly166Glu), each in a single heterozygous individual. Site 2314 is predicted to be tolerated/benign and site 2612 is predicted to be tolerated/possibly damaging by SIFT and PolyPhen, respectively (Table [2](#Tab2){ref-type="table"}a). A previously described (site 2667) as well as two novel synonymous SNPs (sites 2220 and 2244) was also identified in the PDR (Table [2](#Tab2){ref-type="table"}b). Not surprisingly, the synonymous sites, unlike the nonsynonymous sites, were identified in more than one individual. The nonsynonymous site 2513 and the synonymous site 2475 identified in the Indo-Pakistani and Japanese samples, respectively, were not identified in the larger PDR sample. We could not confirm the recently reported nonsynonymous Thr45Met in any of the populations re-sequenced here (Miller et al. [@CR23]).

The newly identified nonsynonymous SNPs are of obvious interest to investigators designing direct genetic association studies because it is assumed that these SNPs are more likely to have a direct impact on the phenotype than noncoding SNPs (Botstein and Risch [@CR1]). However, nonsynonymous SNPs are only informative if they occur at an appreciable frequency in the general population or are enriched among individuals with specific diseases/outcomes. To better characterize the allele and genotype frequency of the possibly damaging nonsynonymous SNPs in a general population, we genotyped sites 2513 and 2612 in a sample of 7,296 DNAs collected by the Centers for Disease Control and Prevention for phase 2 of the National Health and Nutrition Examination Survey (NHANES) III. In \>14,000 chromosomes examined, no individual was heterozygous for site 2513. For site 2612, we identified two heterozygous individuals. Thus, these two sites are rare in the general population with a minor allele frequency well below 1%.

CRP and dbSNP {#Sec8}
-------------

For both direct and indirect association study designs, one common concern for investigators is the reliance on public databases for available genetic variations in the gene or region of interest. Previous work examining the quality and completeness of dbSNP suggests that \>50% of the reported SNPs are common (Carlson et al. [@CR4]; Jiang et al. [@CR19]; Reich et al. [@CR28]). These studies also demonstrate that a considerable fraction of SNPs in dbSNP (\~40%) cannot be found in other samples, suggesting these reported SNPs are either very rare or artifacts (Carlson et al. [@CR4]; Jiang et al. [@CR19]). To examine these issues for *CRP*, we mapped the SNPs identified here by deep re-sequencing to those found within dbSNP in the gene *CRP*.

For build 125 of dbSNP, 17 DNA variations are reported in the gene *CRP*. Five of the 17 DNA variations reported by dbSNP are considered validated SNPs. To directly compare SNPs reported in dbSNP to the SNPs discovered in the various populations reported here, we only considered the 21 SNPs we annotated in exons 1 and 2 and intron 1. Only six of the 17 dbSNP reports (35%) can be confirmed by the re-sequencing efforts described here, and all six of these SNPs were common SNPs reported by SeattleSNPs. These six SNPs included the five validated SNPs. More than half of the dbSNP submissions (11/17; 64.7%) cannot be confirmed by any of the populations re-sequenced here. Overall, 71.4% of the *CRP* variants identified here are not currently found in dbSNP; however, none of these SNPs is common among the chromosomes re-sequenced here. Thus, dbSNP is most likely complete for common variation but incomplete for rare variation in *CRP*, as expected.

TagSNPs for association studies {#Sec9}
-------------------------------

Another common concern for investigators is that an optimal subset of SNPs (termed "tagSNPs") must be chosen from the information at hand for genotyping in a genetic association study. The tagSNP or "indirect" approach can be an economical approach because only SNPs that maintain the genetic diversity of the gene or region (as defined by linkage disequilibrium) are genotyped (Carlson et al. [@CR5]; Stram [@CR33]). Recent evidence suggests that tagSNPs are transferable across populations of similar race/ethnicity without loss of information (Ke et al. [@CR41]). SeattleSNPs routinely chooses tagSNPs for European-American and African-American population samples, and it is expected that these tagSNPs will be sufficient for association studies genotyping samples of European- and African-descent. However, it is not know how well these tagSNPs perform when genotyped in an admixed population such as Mexican-Americans.

Previous admixture studies suggest that Mexican or Mexican-American populations have European, African, and Asian/Amerindian ancestry, with proportions estimated at approximately 40--60, 3--5, and 30--50%, respectively (Hanis et al. [@CR37]; Long et al. [@CR38]; Collins-Schramm et al. [@CR40]; Salari et al. [@CR39]). To understand how much, if any, diversity information is lost in genotyping SeattleSNPs tagSNPs in a Mexican or Mexican-American sample, we compared tagSNPs determined for a combined population of African- and European-Americans (Fig. [2](#Fig2){ref-type="fig"}a, b) to those determined for the Mexican population sample (Fig. [2](#Fig2){ref-type="fig"}c) using LDSelect at MAF\>5% and *r*^2^\>0.64. For the Mexican population sample of 20 chromosomes, five tagSNPs were identified for genotyping. All five tagSNPs were represented among tagSNPs chosen for the European- and African-American combined sample and are sufficient to capture the genetic diversity of the locus within the Mexican population sample. Interestingly, the Asian population sample of Chinese, Japanese, and Southeastern Asians is also well represented by *CRP* tagSNPs chosen from a combined European- and African-American population sample (Fig. [2](#Fig2){ref-type="fig"}d). Fig. 2TagSNPs chosen for four population samples. TagSNPs were chosen from SNPs with MAF \>5% using LDSelect at *r*^2^\>0.64

Conclusions {#Sec10}
===========

By re-sequencing \~1,000 chromosomes ascertained from several population samples, we have catalogued novel coding and noncoding DNA variants in *CRP*. The vast majority of these novel SNPs were rare, consistent with previous observations from candidate gene deep re-sequencing projects (Glatt et al. [@CR16]). We also identified common *CRP* variation in the Asian and Mexican-descent population samples that overlapped to a great extent with common variation identified by SeattleSNPs in the European-American and African-American population samples.

For *CRP*-specific genetic association studies, these re-sequencing data suggest that *CRP* common SNPs are in dbSNP and that common disease/common variant study designs using a tagSNP approach can be applied to several population samples with very little population-specific modification. That is, if the most diverse population (e.g., African-descent populations) is considered in tagSNP selection for *CRP*, genetic diversity for *CRP* in other population samples will be well represented. However, if only a less diverse population were considered for tagSNP selection (e.g., European-descent populations), one tagSNP (rs3093058) associated with serum CRP levels (Carlson et al. [@CR6]; D. C. Crawford et al., submitted) would not be represented for *CRP* diversity observed in African-Americans and Mexican-Americans. This issue should be considered when designing genetic association studies in non-European population samples using public SNP resources such as HapMap or dbSNP (Clark et al. [@CR8]).

The re-sequencing data for *CRP* also suggest that coding variation, if not identified in a small re-sequencing sample, is very rare in the general population. These results are not entirely unexpected because the samples sizes used in variation discovery for the present study are based on population genetics theory (i.e., effective population size and mutation rate) and are designed to sufficiently estimate the allele frequency for SNPs with a minor allele frequency of \>5--10% (Kruglyak and Nickerson [@CR21]). Indeed, tagSNPs determined in SeattleSNPs were recently genotyped in three larger studies and demonstrated that allele frequencies estimated in the SeattleSNPs sample of 47 individuals is nearly identical to the allele frequencies estimated in the larger studies (Carlson et al. [@CR6]; D. C. Crawford et al., submitted; L. A. Lange et al., in preparation).

While the coding variation identified in the present study was rare in the general population, there is a possibility that *CRP* coding variation is strongly associated with a phenotype and could be enriched in a case population. The challenge, of course, is to predict a disease or extreme phenotype given that a putative mutation has been identified. Given that the nonsynonymous SNP in *CRP* may be damaging to the gene product, we may expect lower levels of serum CRP in heterozygous individuals compared with homozygous individuals for the common allele. Alternately, we may expect individuals heterozygous for these SNPs are unable to mount a proper acute phase response compared with individuals homozygous for the common allele. There is no known human deficiency for CRP, but there are several phenotypes associated with lack of acute phase response (reviewed in Pepys and Hirschfield [@CR25]). Unfortunately, the CRP assay used in NHANES III is not as sensitive compared with currently used assays (Centers for Disease Control and Prevention [@CR7]), so we cannot determine how low the serum CRP levels are for the two individuals who are heterozygous for the nonsynonymous *CRP* SNP (D. C. Crawford et al., submitted).

The possibility that deleterious variation may exist in human *CRP* is intriguing. In addition to providing information for future functional *CRP* studies in humans, these deep re-sequencing data provide an opportunity to explore the effects of possibly deleterious genetic variation using model organisms and in vitro assays. One obvious choice for modeling SNP effects in context with various environmental exposures is the mouse (MacAuley and Ladiges [@CR22]). However, for *CRP*, the mouse is not an ideal model because its *CRP* gene does not function like the human *CRP* gene (Pepys and Hirschfield [@CR25]). Nevertheless, the *CRP* example demonstrates the potential usefulness of identifying coding variants through deep re-sequencing that may be taken forward into other meaningful experiments that specialize in function.

In summary, we describe here the genetic architecture of *CRP* with special emphasis on the detection and characterization of rare variants. While we were able to describe novel nonsynonymous variants for *CRP*, we were unable to describe these variants at an appreciable frequency when genotyped in the general population making it impossible to explore the impact of these variants on serum CRP. Given this situation, for a quantitative trait such as CRP, it may be more efficient to re-sequence individuals at the extreme low and high end of the distribution in the search for rarer SNPs that impact the phenotype of interest (Cohen et al. [@CR10]; Cohen et al. [@CR9]). In the age of more efficient, high throughput genotyping (Hinds et al. [@CR17]; Shen et al. [@CR30]), it may be that re-sequencing used in conjunction with genotyping using different study designs is required to fully appreciate the spectrum of genetic variants associated with a human phenotype of interest.

Websites {#Sec11}
========

EntrezGene <http://www.ncbi.nih.gov/entrez/query.fcgi?db=gene>

NHANES: <http://www.cdc.gov/nchs/nhanes.htm>

PolyPhen: <http://www.tux.embl-heidelberg.de/ramensky/>

SeattleSNPs Program for Genomic Applications: <http://www.pga.gs.washington.edu/>

SIFT: <http://www.blocks.fhcrc.org/sift/SIFT_BLink_submit.html>
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